Mechanisms of resistance among respiratory tract pathogens

被引:8
作者
Jacobs, MR
Anon, J
Appelbaum, PC
机构
[1] Case Western Reserve Univ, Sch Med, Dept Pathol, Univ Hosp Cleveland, Cleveland, OH 44106 USA
[2] Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA USA
[3] Milton S Hershey Med Ctr, Dept Pathol, Hershey, PA 17033 USA
关键词
D O I
10.1016/j.cll.2004.03.011
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Antimicrobial resistance among respiratory tract pathogens represents a significant health care threat. Identifying the antimicrobial agents that remain effective in the presence of resistance, and knowing why, requires a thorough understanding of the mechanisms of action of the various agents as well as the mechanisms of resistance demonstrated among respiratory tract pathogens. The primary goal of antimicrobial therapy is to eradicate the pathogen, via killing or inhibiting bacteria, from the site of infection; the defenses of the body are required for killing any remaining bacteria. Targeting a cellular process or function specific to bacteria and not to the host limits the toxicity to patients. Currently, there are four general cellular targets to which antimicrobials are targeted: cell wall formation and maintenance, protein synthesis, DNA replication, and folic acid metabolism. Resistance mechanisms among respiratory tract pathogens have been demonstrated for all four targets. In general, the mechanisms of resistance used by these pathogens fall into one of three categories: enzymatic inactivation of the antimicrobial, prevention of intracellular accumulation, and modification of the target site to which agents bind to exert an antimicrobial effect. Resistance to some agents can be overcome by modifying the dosage regimens (eg, using high-dose therapy) or inhibiting the resistance mechanism (eg, beta-lactamase inhibitors), whereas other mechanisms of resistance can only be overcome by using an agent from a different class. Understanding the mechanisms of action of the various agents and the mechanisms of resistance used by respiratory tract pathogens can help clinicians identify the agents that will increase the likelihood of achieving optimal outcomes.
引用
收藏
页码:419 / +
页数:37
相关论文
共 124 条
[71]   Superbugs: How they evolve and minimize the cost of resistance [J].
Donald E. Low ;
James D. Kellner ;
Gerard D. Wright .
Current Infectious Disease Reports, 1999, 1 (5) :464-469
[72]   Experimental study of the virulence of Streptococcus pneumoniae with reduced susceptibility to penicillin [J].
Magnúsdóttir, AB ;
Hermansson, A ;
Melhus, Å .
INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2000, 55 (01) :1-9
[73]   Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults [J].
Mandell, LA ;
Bartlett, JG ;
Dowell, SF ;
File, TM ;
Musher, DM ;
Whitney, C .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (11) :1405-1432
[74]   Mechanism of sulfonamide resistance in clinical isolates of Streptococcus pneumoniae [J].
Maskell, JP ;
Sefton, AM ;
Hall, LMC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2121-2126
[75]   Multiple mutations modulate the function of dihydrofolate reductase in trimethoprim-resistant Streptococcus pneumoniae [J].
Maskell, JP ;
Sefton, AM ;
Hall, LMC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) :1104-1108
[76]   Distribution of Streptococcus pneumoniae resistant to penicillin in the USA and in-vitro susceptibility to selected oral antibiotics [J].
Mason, EO ;
Lamberth, L ;
Lichenstein, R ;
Kaplan, SL .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 36 (06) :1043-1048
[77]  
Massova I, 1998, ANTIMICROB AGENTS CH, V42, P1
[78]  
Massova I, 1999, CURR PHARM DESIGN, V5, P929
[79]   Antibiotic resistance in microbes [J].
Mazel, D ;
Davies, J .
CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 56 (9-10) :742-754
[80]  
MAZZEI T, 1993, J ANTIMICROB CHEMOTH, V31, P1